NCT02168140 2024-02-13CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin LymphomaWake Forest University Health SciencesPhase 1 Completed16 enrolled
NCT01326702 2019-12-16Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid TumorsNational Cancer Institute (NCI)Phase 1/2 Completed43 enrolled 18 charts
NCT01110135 2017-05-24Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple MyelomaUniversity of WashingtonPhase 2 Completed43 enrolled 5 charts